RxDoctor Payments Data

Jonathan Lin, MD

Family Medicine · Richardson, TXNPI 1821006040

Payments from drug & device makers

$1,657in general payments, 2019–2025

Across 92 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$311
  • AbbVie$231
  • GSK$174
  • Novo Nordisk$164
  • Abbott$114
  • Otsuka America Pharmaceutical, Inc.$90
  • plus $575 from 15 others

What the payments were for

  • Food & beverage$1,60997%
  • Education$493%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,657 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$98,921
Medicare patients
175
Services billed
1,191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin47$62,804
OzempicSemaglutide53$56,882
FarxigaDapagliflozin Propanediol37$43,561
EliquisApixaban34$34,384
JanuviaSitagliptin Phosphate15$16,126
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$6,413
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide74$3,198
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$2,725
Metoprolol Succinate183$2,395
Olmesartan Medoxomil206$1,968
Atorvastatin Calcium319$1,964
Metformin Hcl168$1,364
Montelukast Sodium106$1,325
Ibandronate Sodium35$1,263
Amlodipine Besylate210$1,199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$48$62,80447 claims
Novo NordiskOzempic$164$56,88253 claims
PfizerEliquis$22$34,38434 claims
MerckJanuvia$13$16,12615 claims
AbbVieSynthroid$231$96835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Richardson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →